Matasar, M. J. Et Al. 2021. CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).. CANCER RESEARCH , vol.81, no.13 .

Matasar, M. J., Capra, M., ÖZCAN, M., Lv, F., Li, W., Yanez, E., ... Sapunarova, K.(2021). CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).. CANCER RESEARCH , vol.81, no.13.

Matasar, Matthew Et Al. "CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).," CANCER RESEARCH , vol.81, no.13, 2021

Matasar, Matthew J. Et Al. "CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).." CANCER RESEARCH , vol.81, no.13, 2021

Matasar, M. J. Et Al. (2021) . "CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).." CANCER RESEARCH , vol.81, no.13.

@article{article, author={Matthew J. Matasar Et Al. }, title={CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).}, journal={CANCER RESEARCH}, year=2021}